ArticleWorld journal of oncology2025
Actionable Mutations and Survival Rates in Non-Small Cell Lung Cancer.
Article in World journal of oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In Jordan, lung cancer ranks as the second most common tumor, and there is an urgent need to explore the genetic landscape of lung cancer. This study aimed to identify the actionable mutations in lung cancer samples in Jordanians by targeted next-generation sequencing (NGS) and to investigate the correlations with clinical and pathological parameters. Methods: Totally, 121samples were prepared for NGS by DNA extractions from formalin-fixed paraffin-embedded (FFPE) blocks, followed by library preparation using the AmpliSeq Colon and Lung panel, which covers mutational hot spot regions for 22 cancer genes. Results: Amongst 121 patients, 88% of those treated for non-small lung carcinoma were successfully analyzed; 35 (29%) carried one mutation or more in actionable genes ( Conclusions: The type and rates of mutations detected for lung tumors in Jordan are relatively similar to those found in other populations previously studied, although some differences exist. However, lung tumors in Jordan require new customized treatment prescriptions based on prior genetic studies, as part of the hoped-for trend toward precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.